3/4/2021 7:47:00 AM
Verrica Pharmaceuticals Q4 Net Loss $13.0 Mln Vs Loss $7.6 Mln Last Year
11/10/2020 7:51:05 AM
Verrica Reports Positive Topline Results From Phase 2 CARE-1 Clinical Study Of VP-102
7/14/2020 7:14:50 AM
Verrica Pharma Gets CRL For NDA For VP-102 For The Treatment Of Molluscum Contagiosum
3/13/2020 7:05:19 AM
Verrica Q4 Net Loss $7.6 Mln Or $0.31 Per Share
11/27/2019 7:09:39 AM
Verrica Pharma Says FDA Accepts NDA Filing For VP-102 For The Treatment Of Molluscum Contagiosum
11/19/2019 7:09:39 AM
Verrica Pharmaceuticals Announces Passing Of Board Member Glenn Oclassen
10/9/2019 7:05:53 AM
Verrica Pharma Appoints Eugene Scavola As EVP, Technical Operations
9/16/2019 7:18:13 AM
Verrica Submits NDA For VP-102 For Treatment Of Molluscum Contagiosum
1/7/2019 7:11:22 AM
Verrica Appoints Neil DeHenes As VP Of Distribution, Trade And Channel Strategy